ProfileGDS4814 / ILMN_1809352
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 7% 1% 8% 3% 12% 6% 8% 4% 9% 17% 1% 1% 2% 3% 3% 1% 2% 1% 1% 9% 16% 2% 4% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)40.27657
GSM780708Untreated after 4 days (C2_1)36.22311
GSM780709Untreated after 4 days (C3_1)40.50278
GSM780719Untreated after 4 days (C1_2)38.52953
GSM780720Untreated after 4 days (C2_2)41.796312
GSM780721Untreated after 4 days (C3_2)39.76856
GSM780710Trastuzumab treated after 4 days (T1_1)40.43478
GSM780711Trastuzumab treated after 4 days (T2_1)39.01214
GSM780712Trastuzumab treated after 4 days (T3_1)40.76219
GSM780722Trastuzumab treated after 4 days (T1_2)42.855117
GSM780723Trastuzumab treated after 4 days (T2_2)36.50821
GSM780724Trastuzumab treated after 4 days (T3_2)36.41351
GSM780713Pertuzumab treated after 4 days (P1_1)37.78292
GSM780714Pertuzumab treated after 4 days (P2_1)38.26123
GSM780715Pertuzumab treated after 4 days (P3_1)38.51423
GSM780725Pertuzumab treated after 4 days (P1_2)35.34991
GSM780726Pertuzumab treated after 4 days (P2_2)37.74642
GSM780727Pertuzumab treated after 4 days (P3_2)33.48731
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)36.34971
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)40.90859
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)42.652516
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)37.85512
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)38.71284